博文
《Antibody Therapeutics》 已经发表的28篇双抗论文集锦
|
Bispecific antibodies (BsAbs), with their unique ability to simultaneously bind two different antigens (often at two different targets), have dramatically expanded the therapeutic landscape of antibody-based treatments. This innovative class of molecules offers enhanced precision in targeting, effectively bridging immune cells to cancer cells for more targeted tumor eradication, or simultaneously blocking two crucial signaling pathways to overcome resistance often encountered with single-target drugs. From their initial conceptualization to the numerous approvals that have transformed clinical practice, the development of bispecific antibodies represents an epic journey of innovation and breakthrough. Particularly, the approval of Tarlatamab by FDA in 2024 to treat extensive-stage small cell lung cancer (ES-SCLC) marks a pivotal milestone, propelling the development of next-generation bispecific and multispecific T-cell engagers to conquer not only liquid, but also solid tumors.
As the official journal of the Chinese Antibody Society, Antibody Therapeutics (Impact Factor 4.5) published by Oxford University Press has played a crucial role in advancing research and development in the bispecific antibody field. Over recent years, the journal has published a substantial volume of high-quality original research and review articles. These publications systematically showcase the latest advancements in antibody design, production, mechanisms of action, preclinical evaluation, and clinical applications. This body of work not only provides invaluable knowledge to the global scientific community but also fosters collaboration and exchange among various research teams in the field.
Of particular note are the 28 articles focusing on bispecific antibodies published in recent years. These publications offer a comprehensive overview of the field, including:
7 reviews that summarize the latest landscapes and key developments in this rapidly evolving area, along with insights from major meetings.
15 research articles detailing the research and development of BsAbs targeting various antigens.
6 articles on new technical advancements in their production, purification, and assays.
These 28 publications offer an invaluable resource for anyone looking to stay current with the exciting advancements in the bispecific antibody field within the biopharma industry. We encourage you to explore them and join us to contribute to this dynamic area.
[1] Effect of allotypic variation of human IgG1 on the thermal stability of disulfide-linked knobs-into-holes mutants of the Fc for stable bispecific antibody design
Hiroki Akiba, Reiko Satoh, Satoshi Nagata, Kouhei Tsumoto
Antibody Therapeutics, Volume 2, Issue 3, July 2019, Pages 65-69
https://doi.org/10.1093/abt/tbz008
[2] Highlights of 2019 Protein Engineering Summit (PEGS) in Boston, USA: advancing antibody-based cancer therapies to the clinic
Hong Li, You Li, Cheng Wang, Shouye Wang, Mitchell Ho
Antibody Therapeutics, Volume 2, Issue 4, October 2019, Pages 79–87
https://doi.org/10.1093/abt/tbz010
[3] Next-Generation Antibody Therapeutics: Discovery, Development and Beyond: highlights of the third annual conference of the Chinese Antibody Society
Hongyu Zhang, Mi Deng, Fen Pei, Shouye Wang, Mitchell Ho
Antibody Therapeutics, Volume 2, Issue 4, October 2019, Pages 99–107
https://doi.org/10.1093/abt/tbz012
[4] Biology drives the discovery of bispecific antibodies as innovative therapeutics
Siwei Nie, Zhuozhi Wang, Maria Moscoso-Castro, Paul D'Souza, Can Lei, Jianqing Xu, Jijie Gu
Antibody Therapeutics, Volume 3, Issue 1, January 2020, Pages 18–62
https://doi.org/10.1093/abt/tbaa003
[5] Highlights of Antibody Engineering and Therapeutics 2019 in San Diego, USA: Bispecific Antibody Design and Clinical Applications
Yong Zhu, Run Shen, Rui Hao, Shouye Wang, Mitchell Ho
Antibody Therapeutics, Volume 3, Issue 2, April 2020, Pages 146–154
https://doi.org/10.1093/abt/tbaa012
[6] Development of bispecific antibodies in China: overview and prospects
Jing Zhang, Jizu Yi, Pengfei Zhou
Antibody Therapeutics, Volume 3, Issue 2, April 2020, Pages 126–145
https://doi.org/10.1093/abt/tbaa011
[7] Current trends and challenges in the downstream purification of bispecific antibodies
Serene W Chen, Wei Zhang
Antibody Therapeutics, Volume 4, Issue 2, April 2021, Pages 73–88
https://doi.org/10.1093/abt/tbab007
[8] An optimal antitumor response by a novel CEA/CD3 bispecific antibody for colorectal cancers
Ninghai Wang, Harshal Patel, Irene C Schneider, Xin Kai, Avanish K Varshney, Li Zhou
Antibody Therapeutics, Volume 4, Issue 2, April 2021, Pages 90–100
https://doi.org/10.1093/abt/tbab009
[9] Development of a reporter gene method to measure the bioactivity of anti-CD38 × CD3 bispecific antibody
Hui Xiong, Fengyan Luo, Pengfei Zhou, Jizu Yi
Antibody Therapeutics, Volume 4, Issue 4, October 2021, Pages 212–221
https://doi.org/10.1093/abt/tbab022
[10] Biological activity validation of a computationally designed Rituximab/CD3 T cell engager targeting CD20+ cancers with multiple mechanisms of action
Wenyan Cai, Jianbo Dong, Sachith Gallolu Kankanamalage, Allison Titong, Jiadong Shi, Zhejun Jia, Bo Wang, Cai Huang, Jing Zhang, Jun Lin, Steven Z Kan, Shuhua Han, Joe Zhou, Yue Liu
Antibody Therapeutics, Volume 4, Issue 4, October 2021, Pages 228–241
https://doi.org/10.1093/abt/tbab024
[11] Productivity and quality improvement for a symmetric bispecific antibody through the application of intensified perfusion cell culture
Yongjun Qin, Rongmei Ma, Yang Li, Yifeng Li, Gong Chen, Weichang Zhou
Antibody Therapeutics, Volume 5, Issue 2, April 2022, Pages 111–120
https://doi.org/10.1093/abt/tbac009
[12] Development of a T cell-redirecting bispecific antibody targeting B-cell maturation antigen for the suppression of multiple myeloma cell growth
Jianxin Huo, Yuhan Huang, Ziying Zheng, Xin Ni Tay, Farouq Bin Mahfut, Wei Zhang, Kong-Peng Lam, Yuansheng Yang, Shengli Xu
Antibody Therapeutics, Volume 5, Issue 2, April 2022, Pages 138–149
https://doi.org/10.1093/abt/tbac012
[13] Role of harvest depth filtration in controlling product-related impurities for a bispecific antibody
Ehsan Espah Borujeni, Weixin Jin, Chun Shao, Naresh Chennamsetty, Xuankuo Xu, Sanchayita Ghose
Antibody Therapeutics, Volume 5, Issue 4, October 2022, Pages 268–279
https://doi.org/10.1093/abt/tbac023
[14] Vector design for enhancing expression level and assembly of knob-into-hole based FabscFv-Fc bispecific antibodies in CHO cells
Han Kee Ong, Ngan T B Nguyen, Jiawu Bi, Yuansheng Yang
Antibody Therapeutics, Volume 5, Issue 4, October 2022, Pages 288–300
https://doi.org/10.1093/abt/tbac025
[15] Ceramic hydroxyapatite chromatography plays a critical role in bispecific antibody purification process for impurity removal
Jessica A Waller, Ji Zheng, Rachel Dyer, Thomas Slaney, Wei Wu, Li Tao, Sanchayita Ghose
Antibody Therapeutics, Volume 6, Issue 1, January 2023, Pages 30–37
https://doi.org/10.1093/abt/tbac030
[16] A novel IgG Fc by computer-aided design enhances heavy-chain heterodimerization in bi- or trispecific antibodies
Bo Wang, Jun Lin, Matthew R Hoag, Meredith Wright, Mingjun Ma, Wenyan Cai, Sachith Gallolu Kankanamalage, Yue Liu
Antibody Therapeutics, Volume 5, Issue 3, July 2022, Pages 216–225
https://doi.org/10.1093/abt/tbac019
[17] Comparative assessment of the binding and neutralization activity of bispecific antibodies against SARS-CoV-2 variants
Alexis Q Dean, Charles B Stauft, Julianne D Twomey, Joshua Tan, Luca Varani, Tony T Wang, Baolin Zhang
Antibody Therapeutics, Volume 6, Issue 1, January 2023, Pages 49-58
https://doi.org/10.1093/abt/tbac032
[18] Preclinical evaluation of ISH0339, a tetravalent broadly neutralizing bispecific antibody against SARS-CoV-2 with long-term protection
Huabing Yang, Yuxin Chen, Dongcheng Jiang, Xiaoli Feng, Ying Xu, Jiayu Wei, Qingcui Zou, Qiaojiang Yang, Jihong Chen, Xiaoling Jiang, Chunling Qin, Zhenzhen Huang, Chongbing Wu, Ying Zhou, Minghua Li, Liusong Yin
Antibody Therapeutics, Volume 6, Issue 2, April 2023, Pages 97-107
https://doi.org/10.1093/abt/tbad003
[19] Efficient production of bispecific antibodies—optimization of transfection strategy leads to high-level stable cell line generation of a Fabs-in-tandem immunoglobin
Shiyong Gong, Chengbin Wu
Antibody Therapeutics, Volume 6, Issue 3, July 2023, Pages 170-179
https://doi.org/10.1093/abt/tbad013
[20] Next generation of multispecific antibody engineering
Daniel Keri, Matt Walker, Isha Singh, Kyle Nishikawa, Fernando Garces
Antibody Therapeutics, Volume 7, Issue 1, January 2024, Pages 37–52,
https://doi.org/10.1093/abt/tbad027
[21] GB12-09, a bispecific antibody targeting IL4Rα and IL31Rα for atopic dermatitis therapy
Feiyan Deng, Yuxin Qiu, Xiangling Zhang, Nining Guo, Junhong Hu, Wenjie Yang, Wei Shang, Bicheng Liu, Suofu Qin
Antibody Therapeutics, Volume 7, Issue 1, January 2024, Pages 77–87,
https://doi.org/10.1093/abt/tbad032
[22] A VHH single-domain platform enabling discovery and development of monospecific antibodies and modular neutralizing bispecifics against SARS-CoV-2 variants
Marisa L Yang, Tom Z Yuan, Kara Y Chan, Lin Ding, Zhen Han, Hector Franco, Carson Holliday, Shruthi Kannan, Edgar Davidson, Benjamin J Doranz, Kartik Chandran, Emily Happy Miller, Jessica A Plante, Scott C Weaver, Eunice Cho, Shweta Kailasan, Lukas Marsalek, Hoa Giang, Yasmina Abdiche, Aaron K Sato
Antibody Therapeutics, Volume 7, Issue 2, April 2024, Pages 164–176,
https://doi.org/10.1093/abt/tbae009
[23] A case study of a bispecific antibody manufacturability assessment and optimization during discovery stage and its implications
Shuang Wang, Weijie Zhang, Baotian Yang, Xudong Zhang, Jing Fang, Haopeng Rui, Zhijian Chen, Jijie Gu, Zhiqiang Chen, Jianqing Xu
Antibody Therapeutics, Volume 7, Issue 3, July 2024, Pages 189–198,
https://doi.org/10.1093/abt/tbae013
[24] Protein language models enable prediction of polyreactivity of monospecific, bispecific, and heavy-chain-only antibodies
Xin Yu, Kostika Vangjeli, Anusha Prakash, Meha Chhaya, Samantha J Stanley, Noah Cohen, Lili Huang
Antibody Therapeutics, Volume 7, Issue 3, July 2024, Pages 199–208,
https://doi.org/10.1093/abt/tbae012
[25] Beyond ADCs: harnessing bispecific antibodies to directly induce apoptosis for targeted tumor eradication
Victor S Goldmacher, Iosif M Gershteyn, Yelena Kovtun
Antibody Therapeutics, Volume 7, Issue 4, October 2024, Pages 351–360,
https://doi.org/10.1093/abt/tbae029
[26] Discovery of a common light chain bispecific antibody targeting PD-1 and PD-L1 by Hybridoma-to-Phage-to-Yeast (H2PtY) platform
Peipei Liu, Chunyin Gu, Xiaodan Cao, Huawei Zhang, Zongda Wang, Yukun Yang, KeDong OuYang, Yingying Zhen, Fangfang Jia, Xianqing He, Haixiang Yu, Sujun Deng
Antibody Therapeutics, Volume 8, Issue 1, January 2025, Pages 1–12,
https://doi.org/10.1093/abt/tbae027
[27] Generation of antagonistic biparatopic anti-CD30 antibody from an agonistic antibody by precise epitope determination and utilization of structural characteristics of CD30 molecule
Hiroki Akiba, Tomoko Ise, Reiko Satoh, Yasuhiro Abe, Kouhei Tsumoto, Hiroaki Ohno, Haruhiko Kamada, Satoshi Nagata
Antibody Therapeutics, Volume 8, Issue 1, January 2025, Pages 56–67,
https://doi.org/10.1093/abt/tbaf002
[28] A novel bispecific antibody CVL006 superior to AK112 for dual targeting of PD-L1 and VEGF in cancer therapy
Chunyan Wang, Hao Huang, Zeng Song, Zhongyuan Li, Jinwen Huang, Liang Cao, Ziai Wu, Junfang Pan, XiaoBing Chen, Xiaokun Shen
Antibody Therapeutics, Volume 8, Issue 3, July 2025, Pages 189–196,
https://doi.org/10.1093/abt/tbaf012
Author of this wechat article: Yuxi Shan
Reviewer: Haiyong Peng
About Antibody Therapeutics:
A peer-reviewed, online, open access journal published by Oxford University Press, Antibody Therapeutics provides a forum for the publication of the latest advances and challenges in the discovery, research, development, manufacturing, and methodology of therapeutic antibodies for the global scientific community. Topics include target and antibody discovery, mechanistic research, new technologies and methods, manufacturing, clinical trials, regulation, policies, and more. Antibody Therapeutics is indexed by the Web of Science, PubMed, and Scopus. It has a CiteScore of 8.4, Impact Factor of 4.5, and over 175,000 full-text downloads during the calendar year of 2024. Antibody Therapeutics invites you to explore the latest breakthroughs on its website and consider the journal as a platform for your scholarly research.
Journal Website: https://academic.oup.com/abt
Contact: abt.editorialoffice@publishingsolutions.net
https://blog.sciencenet.cn/blog-3592244-1509372.html
上一篇：Antibody Therapeutics 2025年首期回顾：抗体药物研发新趋势全景呈现
下一篇：圣因生物与礼来达成12亿美元RNAi全球合作
